Development of more potent atrial natriuretic factor (ANF) analogs

Add time:09/02/2019    Source:sciencedirect.com

Four modified atrial natiuretic factor (ANF) analogs were designed and synthesized by the solid-phase method. Using human ANF-(99–126) as the reference compound the receptor binding affinity and biological activity of these analogs were examined by radioreceptor assay and in vivo experiments. PLO68, a 21 amino peptide with structural modifications des-Ser103,104-[Mpr105, D-Ala107,114]APII-amide exhibited 2.5 and 2.2 fold more activity than human ANF-(99–126) in lowering blood pressure and causing natriuresis in urethane anesthetized rats. Receptor binding assays using rat lung membranes showed that PLO68 had a Kd of 200 ± 12 pM compared to a Kd of 620 ± 12 pM for human ANF-(99–126). Similar chemical modifications, except for substitution of glycine and alanine at the positions 115 and 118, and 120 by D-alanine resulted in three analogs PLO63 and PLO64, PLO67 respectively. PLO63, PLO64 and PLO69 had similar affinities and in vivo potency as human ANF-(99–126). These data suggest that the structural modifications made in PLO68 can cause an increase in the receptor binding ability and an enhancement of biological activities.

We also recommend Trading Suppliers and Manufacturers of atrial natriuretic factor (7-23)amide (cas 114191-94-5). Pls Click Website Link as below: cas 114191-94-5 suppliers

Prev:Release of atrial natriuretic factor induced by the A1 adenosine receptor agonist 2-chloro-N6-cyclopentyl-adenosine in the rat
Next:Backbone dynamics of oxidised and reduced forms of human atrial natriuretic peptide☆)